Why Is CULLINAN THERAPEUTIC (CGEM) Stock Down Today?

Why CGEM stock is down today

Cullinan Therapeutics stock fell 12.12% to $14.83 on Wednesday, marking one of the largest declines in the biotech sector. The drop came despite recent positive developments in the company's pipeline and a favorable interim analysis of its REZILIENT3 trial. The sell-off appears to reflect broader market weakness in biotech and investor caution following recent insider selling activity.

What Happened

Cullinan Therapeutics outlined key milestones for the fourth quarter of 2026 across its immunology and oncology T cell engager portfolio, including data presentations at major conferences. The company also filed a Form 8-K with the SEC, disclosing Regulation FD updates and other events. Despite these developments, the stock opened at $16.88 and quickly declined throughout the session, hitting a low of $14.80 before closing near that level.

The broader biotech sector experienced a sharp downturn, with Cullinan among the hardest-hit names. The stock’s decline occurred alongside a broader sell-off in the top 2% of biotech stocks. Meanwhile, positive results from the REZILIENT3 trial, including a favorable hazard ratio for zipalertinib, were already known to the market. Analysts from BTIG and HC Wainwright have maintained Buy ratings and raised price targets, but these have not yet translated into investor confidence.

What The Data Shows

Cullinan’s stock has declined 9.5% over the last eight sessions, from $20.59 to $18.63. The stock currently trades at $14.83, well below its 52-week high of $23.19. The session saw 0.7 million shares traded, which is 0.8 times the 3-month daily average. The stock also printed two fresh 52-week lows on September 24. In the last 90 days, insiders have sold a total of $923,000 worth of shares, with the most recent sale reported on September 10.

What To Watch

Cullinan Therapeutics is scheduled to present further data from its REZILIENT3 trial in the coming weeks. Investors will be watching for additional coverage and analyst reactions, as well as any new developments in its pipeline.